--- title: "ISEC Healthcare (Catalist:40T) Q1 EPS Stability Tests Growth Narratives After Recent Slowdown" type: "News" locale: "en" url: "https://longbridge.com/en/news/284091477.md" description: "ISEC Healthcare (Catalist:40T) reported Q1 2026 revenue of S$18.6 million and net income of S$2.8 million, with an EPS of S$0.0049. Despite a five-year earnings growth rate of 13.6%, recent growth has slowed to 2.9%. The trailing net profit margin decreased from 17.0% to 16.4%. The shares trade at S$0.33 with a P/E of 14.5x, below industry averages, while the DCF fair value is S$0.10, indicating potential valuation concerns. Investors are advised to consider long-term trends and valuation before making decisions." datetime: "2026-04-25T22:05:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284091477.md) - [en](https://longbridge.com/en/news/284091477.md) - [zh-HK](https://longbridge.com/zh-HK/news/284091477.md) --- # ISEC Healthcare (Catalist:40T) Q1 EPS Stability Tests Growth Narratives After Recent Slowdown ISEC Healthcare (Catalist:40T) has kicked off Q1 2026 with revenue of S$18.6 million and net income of S$2.8 million, translating into basic EPS of S$0.0049. Over recent quarters the company has reported revenue moving from S$17.9 million in Q1 2025 to around S$20.7 million in Q4 2025, while quarterly EPS has ranged between S$0.0035 and S$0.0068. This sets up the latest results against a backdrop of steady profitability and slightly softer margins. See our full analysis for ISEC Healthcare. With the headline numbers on the table, the next step is to assess how this earnings update aligns with the prevailing views on ISEC Healthcare's growth, profitability, and risk profile. Curious how numbers become stories that shape markets? Explore Community Narratives Catalist:40T Revenue & Expenses Breakdown as at Apr 2026 ## 13.6% multi year growth versus 2.9% latest year - Over the trailing 12 months, net income was S$13.1 million with Basic EPS of S$0.0228, compared with five year earnings growth of 13.6% per year and one year earnings growth of 2.9%. - What stands out for a more bullish view is that the five year earnings growth rate of 13.6% per year sits alongside trailing net profit margin of 16.4%, yet the latest 12 month earnings growth of 2.9% is lower than that multi year rate. - This combination of a positive multi year growth rate and a slower recent 12 month growth outcome gives you two different speeds to compare when thinking about how consistent performance has been. - At the same time, trailing revenue of S$80.0 million and net income of S$13.1 million show that profitability remains meaningful in dollar terms even with the slightly softer growth figure. ## Margins at 16.4% after prior 17.0% - Trailing net profit margin sits at 16.4% on S$79.97 million of revenue and S$13.12 million of net income, compared with 17.0% a year earlier. - Critics who focus on pressure on profitability will point to the move from a 17.0% margin to 16.4%, but the recent quarterly and trailing numbers together give a more rounded picture. - Across the last six reported quarters, net income per quarter ranged from S$1.99 million to S$3.91 million, with Q1 2026 at S$2.84 million, which helps you see how earnings have sat within a fairly tight band. - The trailing 12 month EPS of S$0.0228 compared with Q1 2026 EPS of S$0.0049 shows how any single quarter fits into the full year earnings that drive valuation ratios. ## P/E of 14.5x and DCF fair value gap - The shares trade at S$0.33, with a P/E of 14.5x that is below the Asian healthcare industry average of 19.9x and the cited peer average of 62.2x, while the DCF fair value given is S$0.10. - What is interesting for a cautious or bearish angle is that the P/E sitting just below the broader market and industry averages comes together with a DCF fair value of S$0.10 and an explicit flag that the shares are highly illiquid. - The P/E of 14.5x against trailing EPS of S$0.0228 reflects how the market is currently valuing the S$13.1 million of trailing net income relative to the S$0.33 share price. - The fact that the DCF fair value of S$0.10 is below the trading level of S$0.33, alongside the comment that the stock is highly illiquid, gives you two concrete data points to weigh when thinking about entry and exit flexibility. For a fuller picture of how other investors are interpreting these numbers, including both optimistic and cautious angles, it can be helpful to see a range of views side by side **📊 Read the what the Community is saying about ISEC Healthcare.** ## Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on ISEC Healthcare's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. The mix of steady profitability, softer recent growth, and valuation questions will land differently for each investor. It is worth checking the details yourself and deciding how they fit your approach, then weighing the 2 key rewards and 1 important warning sign ## See What Else Is Out There ISEC Healthcare's slower recent 2.9% earnings growth, slight margin compression, and share price above the DCF fair value highlight some valuation and growth concerns. If you are questioning whether this setup justifies the current P/E and limited liquidity, compare it with companies screened as 231 high quality undervalued stocks to see if your capital could work harder elsewhere. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [40T.SG](https://longbridge.com/en/quote/40T.SG.md) ## Related News & Research - [Assessing Shizuoka Financial Group (TSE:5831) Valuation After FY 2026 Results And Board Leadership Review](https://longbridge.com/en/news/286786560.md) - [ZAWYA: RAKBANK and Emirates Growth Fund signed strategic MOU at Make It in the Emirates to accelerate SME Growth](https://longbridge.com/en/news/286536882.md) - [NIO Q1 Earnings Date Set for May 21 — Is This EV Stock Ready for a Breakout?](https://longbridge.com/en/news/286870895.md) - [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md) - [AI is not replacing workers on a large scale so far, says Bank of Canada](https://longbridge.com/en/news/286540351.md)